Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
4
67%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

completed467%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_1

Study of Temzolomide and Gleevec in Advanced Melanoma

NCT00667953
completedphase_2

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

NCT03660761
terminatedphase_2

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT01186406
completedphase_2

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

NCT00187486
completedphase_1

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

NCT00527761
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00667953Phase 1

Study of Temzolomide and Gleevec in Advanced Melanoma

Terminated
NCT03660761Phase 2

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Completed
NCT01186406Phase 2

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Terminated
NCT00187486Phase 2

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

Completed
NCT00527761Phase 1

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

Completed
NCT00165230Phase 2

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6